DK1503788T3 - Behandling af alpha-galactosidase A-deficiens - Google Patents

Behandling af alpha-galactosidase A-deficiens

Info

Publication number
DK1503788T3
DK1503788T3 DK03726489.2T DK03726489T DK1503788T3 DK 1503788 T3 DK1503788 T3 DK 1503788T3 DK 03726489 T DK03726489 T DK 03726489T DK 1503788 T3 DK1503788 T3 DK 1503788T3
Authority
DK
Denmark
Prior art keywords
deficiency
galactosidase
alpha
treatment
methods
Prior art date
Application number
DK03726489.2T
Other languages
English (en)
Inventor
Douglas A Treco
Kenneth Loveday
Marianne Borowski
Original Assignee
Shire Human Genetic Therapies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shire Human Genetic Therapies filed Critical Shire Human Genetic Therapies
Application granted granted Critical
Publication of DK1503788T3 publication Critical patent/DK1503788T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/54—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving glucose or galactose
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01022—Alpha-galactosidase (3.2.1.22)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/10—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Obesity (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
DK03726489.2T 2002-04-25 2003-04-25 Behandling af alpha-galactosidase A-deficiens DK1503788T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37558402P 2002-04-25 2002-04-25
PCT/US2003/013063 WO2003090695A2 (en) 2002-04-25 2003-04-25 TREATMENT OF α-GALACTOSIDASE A DEFICIENCY

Publications (1)

Publication Number Publication Date
DK1503788T3 true DK1503788T3 (da) 2011-10-17

Family

ID=29270665

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03726489.2T DK1503788T3 (da) 2002-04-25 2003-04-25 Behandling af alpha-galactosidase A-deficiens

Country Status (12)

Country Link
US (6) US20040071686A1 (da)
EP (2) EP1503788B1 (da)
JP (5) JP5570677B2 (da)
AT (1) ATE514430T1 (da)
AU (2) AU2003228722B2 (da)
BR (2) BR122017016940B8 (da)
CA (1) CA2483270C (da)
DK (1) DK1503788T3 (da)
ES (1) ES2367257T3 (da)
IL (4) IL164757A0 (da)
NZ (1) NZ536361A (da)
WO (1) WO2003090695A2 (da)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR122017016940B8 (pt) 2002-04-25 2021-07-27 Transkaryotic Therapies Inc método para preparação de uma composição farmacêutica compreendendo alfa-galactosidase a
US7442372B2 (en) 2003-08-29 2008-10-28 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
US8052667B2 (en) 2004-09-07 2011-11-08 Velico Medical, Inc. Apparatus for prolonging survival of platelets
AU2005295467B2 (en) * 2004-10-15 2011-07-07 Velico Medical, Inc. Compositions and methods for prolonging survival of platelets
WO2007097934A2 (en) * 2006-02-17 2007-08-30 Elusys Therapeutics, Inc. Methods and compositions for using erythrocytes as carriers for delivery of drugs
US20100144008A1 (en) * 2006-12-21 2010-06-10 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Treatment of fabry disease
EP3399025B1 (en) * 2007-03-23 2025-05-07 Wisconsin Alumni Research Foundation Somatic cell reprogramming
EP2192924B1 (en) 2007-08-20 2017-10-11 Protalix Ltd. Saccharide-containing protein conjugates and uses thereof
US20100291060A1 (en) * 2007-08-29 2010-11-18 Shire Human Genetic Therapies, Inc Subcutaneous administration of alpha-galactosidase a
WO2011061736A1 (en) * 2009-11-17 2011-05-26 Protalix Ltd. Alkaline alpha galactosidase for the treatment of fabry disease
US9194011B2 (en) 2009-11-17 2015-11-24 Protalix Ltd. Stabilized alpha-galactosidase and uses thereof
CA2805413A1 (en) 2010-06-25 2011-12-29 Shire Human Genetic Therapies, Inc. Methods and compositions for cns delivery of heparan n-sulfatase
EP2588130B1 (en) * 2010-06-25 2016-08-17 Shire Human Genetic Therapies, Inc. Cns delivery of therapeutic agents
ES2896060T3 (es) 2010-06-25 2022-02-23 Shire Human Genetic Therapies Métodos y composiciones para la administración al SNC de arilsulfatasa A
AU2011270670B2 (en) 2010-06-25 2017-01-12 Takeda Pharmaceutical Company Limited Methods and compositions for CNS delivery of arylsulfatase A
UA115649C2 (uk) 2010-06-25 2017-12-11 Шае Хюмен Дженетік Терапіс, Інк. Способи та композиції для доставки до цнс ідуронат-2-сульфатази
CA2823592C (en) 2011-01-03 2021-11-23 The Regents Of The University Of California High density epidural stimulation for facilitation of locomotion, posture, voluntary movement, and recovery of autonomic, sexual, vasomotor, and cognitive function after neurological injury
RS60129B1 (sr) 2011-01-20 2020-05-29 Protalix Ltd Kompozicije alfa-galaktozidaze
PL2733218T3 (pl) * 2011-07-14 2018-08-31 Grifols, S.A. Szybka i dokładna analiza sjalilacji białek
US9393409B2 (en) 2011-11-11 2016-07-19 Neuroenabling Technologies, Inc. Non invasive neuromodulation device for enabling recovery of motor, sensory, autonomic, sexual, vasomotor and cognitive function
WO2013096899A2 (en) 2011-12-23 2013-06-27 Shire Human Genetic Therapies, Inc. Stable formulations for cns delivery of arylsulfatase a
HK1209625A1 (en) * 2012-07-17 2016-04-08 Amicus Therapeutics, Inc. Alpha-galactosidase a and 1-deoxygalactonojirimycin co-formulation
US10155027B2 (en) 2012-07-17 2018-12-18 Amicus Therapeutics, Inc. Alpha-galactosidase A and 1-deoxygalactonojirimycin co-formulation for the treatment of fabry disease
WO2014144785A1 (en) 2013-03-15 2014-09-18 The Regents Of The University Of California Multi-site transcutaneous electrical stimulation of the spinal cord for facilitation of locomotion
CA2925754C (en) 2013-09-27 2023-02-21 The Regents Of The University Of California Engaging the cervical spinal cord circuitry to re-enable volitional control of hand function in tetraplegic subjects
ES3030960T3 (en) * 2013-10-31 2025-07-02 Amgen Inc Use of monensin to regulate glycosylation of recombinant proteins
US20170360900A1 (en) 2014-12-22 2017-12-21 Codexis, Inc. Human alpha-galactosidase variants
US9981021B1 (en) 2015-04-09 2018-05-29 Kinetiq, Inc. Subcutaneous therapeutic enzyme formulations, uses, and methods for generating thereof
GB201508025D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Fabry disease gene therapy
US11097122B2 (en) 2015-11-04 2021-08-24 The Regents Of The University Of California Magnetic stimulation of the spinal cord to restore control of bladder and/or bowel
WO2017170896A1 (ja) * 2016-03-30 2017-10-05 国立大学法人徳島大学 マンノース－６－リン酸基含有糖蛋白質の製造方法、及び蛍光基結合型マンノース－６－リン酸基含有糖蛋白質の細胞内分布を検出する方法
CA3048151A1 (en) * 2017-01-05 2018-07-12 Protalix Ltd. Therapeutic regimen for the treatment of fabry using stabilized alpha-galactosidase
TW201829770A (zh) * 2017-01-10 2018-08-16 美商阿米庫斯醫療股份有限公司 用於治療fabry氏病之重組α-半乳糖苷酶A
WO2018148844A1 (en) 2017-02-17 2018-08-23 The University Of British Columbia Apparatus and methods for maintaining physiological functions
US12434068B2 (en) 2017-05-23 2025-10-07 The Regents Of The University Of California Accessing spinal networks to address sexual dysfunction
DE20168827T1 (de) 2017-06-30 2021-01-21 Gtx Medical B.V. System zur neuromodulierung
US20200206323A1 (en) * 2017-09-08 2020-07-02 The Nemours Foundation An agent, a device and a blood-circulation system for treating lysosomal storage diseases, and a method for treating lysosomal storage diseases
US12357828B2 (en) 2017-12-05 2025-07-15 Ecole Polytechnique Federale De Lausanne (Epfl) System for planning and/or providing neuromodulation
US11992684B2 (en) 2017-12-05 2024-05-28 Ecole Polytechnique Federale De Lausanne (Epfl) System for planning and/or providing neuromodulation
US12478777B2 (en) 2018-08-23 2025-11-25 The Regents Of The University Of California Non-invasive spinal cord stimulation for nerve root palsy, cauda equina syndrome, and restoration of upper extremity function
EP3653256B1 (en) 2018-11-13 2022-03-30 ONWARD Medical N.V. Control system for movement reconstruction and/or restoration for a patient
MX2021007552A (es) 2018-12-20 2021-08-11 Codexis Inc Variantes de alfa-galactosidasa humana.
EP3695878B1 (en) 2019-02-12 2023-04-19 ONWARD Medical N.V. A system for neuromodulation
EP3972683A4 (en) 2019-05-22 2023-11-08 The Regents Of The University Of California TRANSCUTANEOUS ELECTRICAL SPINAL CORD NEUROMODULATOR AND USES THEREOF
EP3824948A1 (en) 2019-11-19 2021-05-26 ONWARD Medical B.V. A planning and/or control system for a neuromodulation system
EP3827871A1 (en) 2019-11-27 2021-06-02 ONWARD Medical B.V. Neuromodulation system
DE19211738T1 (de) 2019-11-27 2021-09-09 Onward Medical B.V. Neuromodulationssystem
IL295818A (en) * 2020-02-28 2022-10-01 Codexis Inc Human alpha-galactosidase variants
EP4035658A1 (en) * 2021-01-27 2022-08-03 Consejo Superior de Investigaciones Científicas (CSIC) Liposomes and its use for enzyme delivery
US12623080B2 (en) 2023-06-21 2026-05-12 Onward Medical N.V. Neuromodulation system

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US658567A (en) * 1899-10-14 1900-09-25 Elmer G Howard Threshing-machine attachment.
US4407957A (en) 1981-03-13 1983-10-04 Damon Corporation Reversible microencapsulation of a core material
EP0159604B1 (en) * 1984-04-09 1990-11-07 Toyo Boseki Kabushiki Kaisha Sustained-release preparation applicable to mucous membrane in oral cavity
US4764376A (en) * 1984-06-18 1988-08-16 Eli Lilly And Company Method of inhibiting aromatase
GB8530631D0 (en) * 1985-12-12 1986-01-22 Ciba Geigy Ag Thrombin inhibitors
US4764378A (en) 1986-02-10 1988-08-16 Zetachron, Inc. Buccal drug dosage form
US5272066A (en) * 1986-03-07 1993-12-21 Massachusetts Institute Of Technology Synthetic method for enhancing glycoprotein stability
US6048729A (en) 1987-05-01 2000-04-11 Transkaryotic Therapies, Inc. In vivo protein production and delivery system for gene therapy
FR2619719B1 (fr) 1987-09-01 1991-05-10 Sanofi Sa Procede d'obtention d'interleukine-2 a partir de cellules eucaryotes, vecteurs necessaires a sa mise en oeuvre et lignees cellulaires hautement productrices
US5179023A (en) * 1989-03-24 1993-01-12 Research Corporation Technologies, Inc. Recombinant α-galactosidase a therapy for Fabry disease
EP0463109A4 (en) 1989-03-24 1992-11-19 Research Corporation Technologies, Inc. Recombinant alpha-galactosidase, a therapy for fabry disease
NZ234453A (en) 1989-07-13 1993-01-27 Sanofi Sa Recombinant dna encoding urate oxidase, and vector, host, protein and pharmaceutical compositions associated therewith
US5382518A (en) 1989-07-13 1995-01-17 Sanofi Urate oxidase activity protein, recombinant gene coding therefor, expression vector, micro-organisms and transformed cells
WO1991003556A1 (en) * 1989-09-05 1991-03-21 Biotechnology Australia Pty Ltd Recombinant product
JP2688854B2 (ja) 1989-10-27 1997-12-10 株式会社ホーネンコーポレーション 糖転移活性の強いα―ガラクトシダーゼの製造法
US5697901A (en) * 1989-12-14 1997-12-16 Elof Eriksson Gene delivery by microneedle injection
US5661132A (en) * 1989-12-14 1997-08-26 Auragen, Inc. Wound healing
AU8768191A (en) 1990-09-28 1992-04-28 Upjohn Company, The Transgenic animals with alzheimer's amyloid precursor gene
US5401650A (en) * 1990-10-24 1995-03-28 The Mount Sinai School Of Medicine Of The City University Of New York Cloning and expression of biologically active α-galactosidase A
US5356804A (en) * 1990-10-24 1994-10-18 Mount Sinai School Of Medicine Of The City Of New York Cloning and expression of biologically active human α-galactosidase A
WO1992013067A1 (en) 1991-01-21 1992-08-06 Genzyme Corporation Production of enzymatically active glucocerebrosidase from recombinant cells
SG47470A1 (en) * 1991-04-25 1998-04-17 Univ Brown Res Found Implantable biocompatible immunoisolatory vehicle for delivery of a selected therapeutic products
WO1993000951A1 (en) 1991-07-02 1993-01-21 Inhale, Inc. Method and device for delivering aerosolized medicaments
US5750376A (en) * 1991-07-08 1998-05-12 Neurospheres Holdings Ltd. In vitro growth and proliferation of genetically modified multipotent neural stem cells and their progeny
WO1993008292A1 (en) 1991-10-16 1993-04-29 Agracetus, Inc. Particle-mediated transformation of animal somatic cells
US5641670A (en) 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
US6270989B1 (en) 1991-11-05 2001-08-07 Transkaryotic Therapies, Inc. Protein production and delivery
US5968502A (en) 1991-11-05 1999-10-19 Transkaryotic Therapies, Inc. Protein production and protein delivery
PT101031B (pt) 1991-11-05 2002-07-31 Transkaryotic Therapies Inc Processo para o fornecimento de proteinas por terapia genetica
US6063630A (en) 1991-11-05 2000-05-16 Transkaryotic Therapies, Inc. Targeted introduction of DNA into primary or secondary cells and their use for gene therapy
US5858751A (en) * 1992-03-09 1999-01-12 The Regents Of The University Of California Compositions and methods for producing sialyltransferases
ES2105262T3 (es) 1992-05-18 1997-10-16 Minnesota Mining & Mfg Dispositivo de suministro de farmaco a traves de las mucosas.
US5785049A (en) 1994-09-21 1998-07-28 Inhale Therapeutic Systems Method and apparatus for dispersion of dry powder medicaments
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5804413A (en) * 1992-07-31 1998-09-08 University Of Pittsburgh Of The Commonwealth System Of Higher Education Herpes simplex virus strains for gene transfer
US5569189A (en) 1992-09-28 1996-10-29 Equidyne Systems, Inc. hypodermic jet injector
ATE220327T1 (de) * 1992-09-29 2002-07-15 Inhale Therapeutic Syst Pulmonale abgabe von aktiven fragmenten des parathormons
US6329191B1 (en) 1993-08-30 2001-12-11 Hawaii Biotechnology Group, Inc. DNA encoding recombinant coffee bean alpha-galactosidase
EP0726964A4 (en) * 1993-09-23 1999-01-13 New England Biolabs Inc INSULATION AND COMPOSITION OF NEW GLYCOSIDASES
DE4339605A1 (de) 1993-11-20 1995-05-24 Beiersdorf Ag Desodorierende Wirkstoffkombinationen auf der Basis von alpha, omega-Alkandicarbonsäuren und Fettsäurepartialglyceriden
US5843015A (en) 1993-12-28 1998-12-01 Becton Dickinson And Company Molecules for iontophoretic delivery
US5789247A (en) * 1994-04-01 1998-08-04 Ballay; Annick Expression in non-tumoral human lymphoblastoid lines with an integrative vector
FR2718357B1 (fr) 1994-04-06 1997-10-03 Defarges Alain Moreau Perfectionnements apportés à un dispositif d'injection par jet sans aiguille.
US5834251A (en) * 1994-12-30 1998-11-10 Alko Group Ltd. Methods of modifying carbohydrate moieties
US5599302A (en) 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
US5780014A (en) * 1995-04-14 1998-07-14 Inhale Therapeutic Systems Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin
US5654007A (en) 1995-06-07 1997-08-05 Inhale Therapeutic Systems Methods and system for processing dispersible fine powders
US6566089B1 (en) * 1996-09-04 2003-05-20 Tularik Inc. Cell-based drug screens for regulators of gene expression
US6458574B1 (en) 1996-09-12 2002-10-01 Transkaryotic Therapies, Inc. Treatment of a α-galactosidase a deficiency
US6083725A (en) * 1996-09-13 2000-07-04 Transkaryotic Therapies, Inc. Tranfected human cells expressing human α-galactosidase A protein
PT1538202E (pt) 1996-09-13 2014-04-22 Shire Human Genetic Therapies Produção de alga-galactosidase a humana
CN1308673A (zh) 1998-05-07 2001-08-15 变更染色体医疗公司 通过同源重组修饰FSHβ基因的表达
HUP0101355A3 (en) 1998-05-07 2003-08-28 Transkaryotic Therapies Inc Ca Genomic sequences upstream of the coding region of the g-csf gene for protein production and delivery
IL125423A (en) 1998-07-20 2004-08-31 Israel State Alkaline alpha-galactosidase having broad substrate specificity
US6749851B2 (en) * 2001-08-31 2004-06-15 Clearant, Inc. Methods for sterilizing preparations of digestive enzymes
BR122017016940B8 (pt) * 2002-04-25 2021-07-27 Transkaryotic Therapies Inc método para preparação de uma composição farmacêutica compreendendo alfa-galactosidase a

Also Published As

Publication number Publication date
US20190255156A1 (en) 2019-08-22
US20040071686A1 (en) 2004-04-15
EP1503788A2 (en) 2005-02-09
AU2003228722B2 (en) 2009-06-25
CA2483270C (en) 2015-03-31
JP2005538941A (ja) 2005-12-22
NZ536361A (en) 2008-05-30
US10245304B2 (en) 2019-04-02
US9523113B2 (en) 2016-12-20
AU2009217430B2 (en) 2012-10-18
JP5570677B2 (ja) 2014-08-13
EP1503788B1 (en) 2011-06-29
JP5981151B2 (ja) 2016-08-31
BRPI0309665B1 (pt) 2019-07-16
US20060177433A1 (en) 2006-08-10
US20170216411A1 (en) 2017-08-03
US20110002908A1 (en) 2011-01-06
ATE514430T1 (de) 2011-07-15
AU2009217430A1 (en) 2009-10-15
IL220043B (en) 2018-02-28
IL280818B (en) 2021-12-01
BR122017016940B8 (pt) 2021-07-27
US7833742B2 (en) 2010-11-16
CA2483270A1 (en) 2003-11-06
JP6225224B2 (ja) 2017-11-01
US11116823B2 (en) 2021-09-14
ES2367257T3 (es) 2011-10-31
WO2003090695A3 (en) 2004-05-06
IL220043A0 (en) 2012-06-28
HK1073608A1 (en) 2005-10-14
JP2014196343A (ja) 2014-10-16
JP2016180003A (ja) 2016-10-13
JP6492139B2 (ja) 2019-03-27
JP2018016630A (ja) 2018-02-01
EP2361631A1 (en) 2011-08-31
IL257056A (en) 2018-06-28
JP2012140431A (ja) 2012-07-26
AU2003228722A1 (en) 2003-11-10
IL257056B (en) 2021-03-25
IL280818A (en) 2021-04-29
WO2003090695A2 (en) 2003-11-06
US20160184409A1 (en) 2016-06-30
EP1503788A4 (en) 2008-09-03
US9267166B2 (en) 2016-02-23
BRPI0309665B8 (pt) 2021-05-25
BR0309665A (pt) 2005-08-16
IL164757A0 (en) 2005-12-18
BR122017016940B1 (pt) 2020-11-10

Similar Documents

Publication Publication Date Title
IL280818B (en) A methods of producing alpha-galactosidase preparations
NO20050427L (no) Carvedilolfosfatsalter og/eller solvater derav, tilsvarende preparater og/eller behandlingsfremgangsmater
NO20034056D0 (no) Proliferative sykdommer
PL374865A1 (en) Treatment of tnf alpha related disorders
DE60314500D1 (de) Diaminopyrimidine und deren verwendung als angiogenesehemmer
DE60325374D1 (de) Systeme und vorrichtungen zur einführung von medizinischen implantaten
CY1107439T1 (el) Μεθοδοι προληψης και θεραπειας μολυνσης απο ιο του γενους flavivirus σε ζωα
DE60322582D1 (de) Oberflächenbehandlung von medizinischem gerät
DK1553950T3 (da) Terapeutisk behandling
DE60220220D1 (de) Blutbehandlungssystem
ITMI20030897A1 (it) Procedimento e apparecchiatura per frazionare sangue.
DK1603584T3 (da) Aplidine til behandling af multipelt myelom
NO20053903D0 (no) Nukleotidlipidesterderivater.
FI20040531A7 (fi) Insuliiniresistenttien tilojen hoitaminen ja diagnosointi
EA200500774A1 (ru) Новая синергетическая комбинация, включающая рофлумиласт и формотерол
NO20005548L (no) Mykobakterieinhibitorer
NO20045343L (no) Ny kombinasjon for behandling av luftveisforstyrrelser
ITRM20020308A1 (it) Apparecchiatura per trattamenti terapeutici, e relativo metodo.
NO20022747L (no) Behandlingsstol
ZA200103745B (en) Therapeutic light source and method.
ITBO20020613A1 (it) Apparecchiatura per il trattamento e la pulizia dentale.
NO20011900L (no) Brönnbehandlingsfluider og fremgangsmåter for anvendelse derav
ZA200103743B (en) Therapeutic light source and method.
BR8303683Y1 (pt) disposiÇço em aparelho para tratamento, particularmente da regiço da face e pescoÇo